Cytokinetics Lands Japan Rights to Aficamten, Earns “Moderate Buy” Consensus
Cytokinetics secured exclusive Japanese rights to its cardiac myosin inhibitor aficamten by Bayer and won FDA approval for aficamten under the brand Myqorzo. A consensus of 21 analysts rated the stock a “Moderate Buy,” with 17 buy, three hold and one sell recommendation.
1. Analyst Ratings Consensus
Twenty-one research firms covering Cytokinetics assigned a consensus recommendation of “Moderate Buy,” broken down as 17 buy, three hold and one sell, reflecting cautious optimism on the company’s growth prospects.
2. Aficamten FDA Approval
The FDA approved aficamten under the brand name Myqorzo for obstructive hypertrophic cardiomyopathy, marking a major regulatory milestone and opening the U.S. market to the company’s lead cardiac myosin inhibitor.
3. Japanese Licensing Deal
Cytokinetics granted Bayer exclusive rights to commercialize aficamten in Japan, accelerating its global rollout and potentially unlocking significant royalty revenue in a high-demand cardiovascular market.